🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Michael J. Nathenson

University of Louisville

ORCID: 0000-0002-8888-4482

Also affiliated with World Education

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates”.

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2250

N/A

0.979DataRank · unranked

35 citations

Michael J. Nathenson, Emanuele Mazzola, Jia‐Ren Lin, Joanna Bagińska, Allison Nau +11 more

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1

JCO Precision Oncology(2020)10.1200/po.19.00287

N/A

0.542DataRank · unranked

36 citations

Michael J. Nathenson, Jia‐Ren Lin, Shaolin Mei, Ziming Du, Karan Malik +8 more

SAR-096: A phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.11544

N/A

0.396DataRank · unranked

13 citations

Margaret von Mehren, Elizabeth A. Handorf, Jeffrey A. Morgan, Michael J. Nathenson, Katherine A. Thornton +10 more